Rituximab/CHOP Significantly Improves Outcomes in Advanced FL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 2
Volume 16
Issue 2

Adding rituximab (Rituxan) to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improves the time to treatment failure and overall survival in elderly patients with previously untreated advanced-stage follicular lymphoma (FL)

• ORLANDO—Adding rituximab (Rituxan) to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improves the time to treatment failure and overall survival in elderly patients with previously untreated advanced-stage follicular lymphoma (FL), according to the results of a prospective randomized trial presented at the 48th Annual Meeting of the American Society of Hematology (abstract 482).

"The addition of rituximab to CHOP was efficacious and had low side effects, suggesting that R-CHOP may offer doctors and patients a better option for treatment of this disease," said lead investigator Christian Buske, MD, of the Department of Medicine, Grosshadern, Ludwig-Maximilians-University, Munich, Germany.

Despite improvements in therapeutic regimens, FL remains incurable in its advanced stages. "Therefore our key challenge for the future is to develop treatment strategies to improve treatment outcome without adding major side effects," he said.

On behalf of his coinvestigators from the German Low Grade Lymphoma Study Group (GLSG), Dr. Buske presented data from the GLSG multicenter phase III, randomized controlled trial of CHOP vs R-CHOP.

The analysis focused on patients over age 60 with advanced-stage untreated FL who were randomized to CHOP alone (n = 112), or rituximab 375 mg/m2 plus CHOP (n = 109). Both groups received six to eight cycles of treatment.

The addition of rituximab to CHOP induced higher overall response rates and significantly prolonged the time to treatment failure (TTF), compared with CHOP alone, Dr. Buske reported. The median TTF for R-CHOP was 5.0 years vs 2.1 years for CHOP alone (P < .0001). The estimated 4-year progression-free survival was 62.2% for R-CHOP, compared with 27.9% for CHOP. Most important, he said, in these older patients, R-CHOP prolonged overall survival, with an estimated 4-year overall survival of 90% after R-CHOP vs 81% after CHOP alone (P = .039).

Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content